key: cord-1029307-e5qhumo5
authors: An, Xuedong; Zhang, YueHong; Duan, Liyun; Jin, De; Zhao, Shenghui; Zhou, RongRong; Duan, Yingying; Lian, Fengmei; Tong, Xiaolin
title: The Direct Evidence and Mechanism of Traditional Chinese Medicine Treatment of COVID-19
date: 2021-01-14
journal: Biomed Pharmacother
DOI: 10.1016/j.biopha.2021.111267
sha: 0dda4100c829bad3610baefe809381532a0b02a0
doc_id: 1029307
cord_uid: e5qhumo5

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third coronavirus causing serious human disease to spread across the world in the past 20 years, after SARS and Middle East respiratory syndrome. As of mid-September 2020, more than 200 countries and territories have reported 30 million cases of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, including 950,000 deaths. Supportive treatment remains the mainstay of therapy for COVID-19. The World Health Organization reported that four candidate drugs, including remdesivir, are ineffective or have little effect on COVID-19. According to China News, 90 % of Chinese patients with COVID-19 use traditional Chinese medicine (TCM), with an effectiveness rate of 80 %, and no deterioration in patient condition. We have compiled the direct evidence of TCM treatment for COVID-19 as of December 31, 2020. We describe the advantages of TCM in the treatment of COVID-19 based on clinical evidence and the required methods for its clinical use. TCM can inhibit virus replication and transcription, prevent the combination of SARS-CoV-2 and the host, and attenuate the cytokine storm and immune deficiency caused by the virus infection. The cooperation of many countries is required to establish international guidelines regarding the use of TCM in patients with severe COVID-19 from other regions and of different ethnicities. Studies on the psychological abnormalities in patients with COVID-19, and medical staff, is lacking; it is necessary to provide a complete chain of evidence to determine the efficacy of TCM in the related prevention, treatment, and recovery. This study aims to provide a reference for the rational use of TCM in the treatment of COVID-19.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may have the outbreak a public health emergency of international concern on January 30, 2020.

SARS-CoV-2 is the third coronavirus causing serious human disease to have spread globally in the past 20 years after severe acute respiratory syndrome (SARS) and

Middle East respiratory syndrome (MERS) (2) . As of mid-September 2020, more than 200 countries and territories have reported a total of 30 million confirmed cases and 950,000 deaths (3), placing a huge social burden and economic pressure on the world.

Traditional Chinese medicine (TCM) has been used in China for more than 2,000 years. During the SARS epidemic, TCM played an important role in reducing mortality and alleviating patients' symptoms (4) . In the absence of specific drugs to 

For patients with COVID-19, long-term infection with SARS-CoV-2 increases the numbers of monocytes, neutrophils, NK cells, and CD4+ T cells but at the same time reduces the total numbers of lymphocytes and CD8+ T cells (19, 20) while producing low levels of neutralizing antibodies (21) . Compared to SARS, SARS-CoV-2 may induce a weak immune response in patients with COVID-19 through "immune stealth", prolonging the recovery process (22, 23) . This is related to the low level of cytosine-phosphate-guanosine in the genome, glycosylation to shield essential elements including the receptor binding domain, RNA shielding, and active blocking of antiviral interferon responses related to viral proteins (24-26).

A large study of 72,314 patients with COVID-19 in China revealed that the mortality rate of patients with diabetes was three times higher than that of patients without diabetes (7.3 % vs. 2.3 %) (27) . Similarly, there is a higher all-cause mortality rate in patients with coronary heart disease (12) and cancer (28) . A possible explanation is that approximately 7-10 days after acquiring COVID-19, there may be a J o u r n a l P r e -p r o o f hyperinflammatory response (cytokine storm) that may cause damage to the microcirculation of different vascular beds. The clinical sequelae include thromboembolic events, renal failure, shock, and multiple organ failure (29) (30) (31) .

COVID-19 can also lead to increased myocardial oxygen consumption, and energy consumption caused by fever, sympathetic nerve activation, and tachycardia (32) . Hypoxic brain damage is aggravated, which may lead to neuronal swelling and cerebral edema, and ultimately nervous system damage (33) . SARS-CoV binds to ACE2 in the pancreatic islet cells, destroys them, and causes acute hyperglycemia; it may cause excessive mortality even in patients without diabetes (34) .

Regarding the treatment regime of COVID-19, the WHO initiated a clinical trial called "Solidarity", evaluating the effect of drugs including remdesivir, chloroquine or hydroxychloroquine, and lopinavir/ritonavir (35) . Recently, interim results revealed that all four candidate drugs, including remdesivir, are ineffective or have little effect J o u r n a l P r e -p r o o f on COVID- 19 (36 

TCM is a treasure of ancient Chinese medicine with a history of more than 2,000 years, unique theories, and rich experience (42) . Evidence from randomized controlled trials shows that TCM can effectively treat chronic diseases such as hypertension and diabetes (43) . For example, Gegen Qinlian decoction can J o u r n a l P r e -p r o o f significantly reduce blood sugar in patients with type 2 diabetes; the mechanism of action is related to structural changes of the intestinal flora that is rich in beneficial bacteria (44) . Literature shows that oseltamivir and maxingshigan-yinqiaosan, separately and in combination, can reduce the duration of fever in patients with H1N1 influenza virus infection, indicating that maxingshigan-yinqiaosan can be used as an alternative treatment in patients with H1N1 influenza infection (45 Figure 1 ). Of course, TCM can show its multi-target advantages for COVID-19patients with multiple organ systems. For example, MXSGD can not only improve fever by regulating the immune system, but also improve patients' cough symptoms. According to a nationwide study of 1,099 patients with COVID-19 from 552 hospitals in China, the most common initial symptoms upon admission were fever (88.7 %); cough (67.8 %) (46) ; shortness of breath (53-80 %); fatigue (38 %); myalgia (15-44 %) ; nausea, vomiting, or diarrhea (15-39 %) ; fatigue (25 %); and rhinorrhea (7 %) (47) . The appearance of these symptoms, such as fever, can increase emotional disorders such as stress and anxiety in patients with SARS (48) as well as 54) . In a retrospective cohort study, the suspected cases were treated with Lianhua Qingwen granules (6 g, three times per day) on the basis of nutritional support. Within 10 days of treatment, the rate of disappearance of fever, cough, and fatigue symptoms in the treatment group was 86.7 %, 55.6 %, and 82.5 %, respectively, which is significantly higher than that in patients who were not treated with Lianhua Qingwen (67.7 %, 30.6 %, and 58.6 %, respectively) (55). In another randomized controlled trial, 283 patients were enrolled and randomly divided into one of three treatment groups: 1) a Western medicine group; 2) a Western medicine, Huoxiang Zhengqi dropping pill, and Lianhua Qingwen granule group; and 3) a pandemic, China has promoted many common prescriptions, including QFPDD and HSYF, which are used not only to remove SARS-CoV-2 from the body, but also to relieve the clinical symptoms of COVID-19.

On January 29, 2020, in the previously mentioned study of 1,099 laboratory-confirmed COVID-19 cases, 926 patients were classified as having nonsevere disease, while 173 had severe disease. Of the patients with severe disease, a composite endpoint event occurred in 43, including admission to the intensive care unit, use of mechanical ventilation, or death (46) . This shows that patients with severe COVID-19 have a worse prognosis and may incur more medical expenditure.

Existing evidence shows that integrating TCM into the treatment of COVID-19 can significantly delay the progression of patients with mild and moderate disease to J o u r n a l P r e -p r o o f severe and critical (59) . Accordingly, it may indirectly assist in suppressing the progress of the epidemic and reducing the medical burden.

A cohort study with a total of 721 patients with COVID-19 included 430 in the Hanshiyi formula (HSYF) group and 291 in the control group. The main outcome was the COVID-19 rate of exacerbation, where it was found that 0 (0.0 %) and 19 (6.5 %) cases in the HSYF and control group, respectively, progressed to severe disease. The difference was statistically significant. After considering gender and age using stratified analysis and propensity score matching, the difference in the aggravation rate between the HSYF and control group remained statistically significant (60).

As of mid-September 2020, there were 950,000 deaths in more than 200 countries and territories due to COVID-19 (3) . According to a retrospective study on 1,305 COVID-19 cases treated at Tongren Hospital of Wuhan University, the risk of death in patients with severe or critical disease was 74.364 times higher than that of patients J o u r n a l P r e -p r o o f with moderate disease, while the risk of death in patients using TCM preparations was lower than that in patients not using TCM (61) . This shows that TCM can be used as a potential treatment method to reduce the mortality of patients with severe and critical disease. Another study confirmed the efficacy of TCM, where a total of 484 patients using TCM and 178 who did not use TCM were included. Propensity score matching resulted in 156 users of TCM being matched with 156 non-users. There was no significant difference between the two groups regarding over 40 baseline variables.

Among them, 13 patients in the TCM group died compared to 36 patients in the non-TCM group. After multi-factor adjustment, the use of TCM resulted in an 82.2 % reduction in the risk of death compared to not using TCM (odds ratio 0.178, 95 % Cl 0.076-0.418), indicating that the use of TCM by patients with severe or critical disease reduces their risk of mortality (62) . 

The abovementioned clinical evidence shows that TCM may effectively improve the symptoms of patients with COVID-19, delay the progression to severe disease, and reduce all-cause mortality. However, due to the critical situation of the epidemic, J o u r n a l P r e -p r o o f there is no direct evidence that the application of TCM alone can be an effective treatment, as all studies are performed on the basis of TCM as a supportive treatment (complementing bed rest, supplementation with water and electrolytes, timely effective oxygen therapy measures, antiviral treatment, antibacterial treatment, and renal replacement therapy). Additionally, TCM may reduce the adverse reactions caused by the use of Western medicine, such as antiviral drugs and corticosteroids, particularly regarding the gastrointestinal and liver-related systems (59) . Therefore, evidence exists that, in the treatment of COVID-19, TCM can be supplemented as a supportive treatment, rendering the effect more significant.

TCM can inhibit SARS-CoV-2 replication and transcription, interfering with the normal physiological functions of the virus, and attenuate a series of infection-related processes, including the cytokine storm, immune abnormalities, and coagulation abnormalities (Table 2, Figure 2 ). 

Coronaviruses, including SARS-CoV-2, are enveloped viruses with a nucleocapsid mainly composed of phosphorylated N protein embedded in a phospholipid double-layer envelope. This envelope plays an important role in virus assembly and release, and it is the key to viral disease (86, 87) . Glycosylated S protein is the main J o u r n a l P r e -p r o o f cause of the host immune response (88) . Since the S protein plays a vital role in the interaction between the virus and cell receptors, it is an important potential target for antiviral agents (89) . The E protein is the smallest transmembrane structural protein of coronaviruses (90) and M proteins. They are composed of functional subunits S1 and S2. The S1 subunit forms a receptor domain (98) that can bind to ACE2 to enter the host cells (99, 100) .

ACE2 is a type of polypeptide that is highly expressed on the surface of epithelial cells, arteriovenous endothelial cells, arterial smooth muscle cells, and small intestinal epithelial cells (98, (101) (102) (103) . The decrease of the ACE2 function after viral infection may lead to renin-angiotensin system dysfunction, which affects blood pressure and fluid/electrolyte balance and enhances respiratory tract inflammation and vascular permeability (104) .

Emodin is an anthraquinone compound that is found in various TCM recipes, and it has been shown to inhibit the interaction between the SARS-CoV S protein and its receptor, ACE2, in a dose-dependent manner (63) . Glycyrrhizic acid can also interfere with the binding of the virus to the ACE2 receptor (105) . With network pharmacology and molecular docking methods, the compounds in Huoxiang Zhengqi oral liquid can also inhibit the interaction between the SARS-CoV S protein and ACE2, thereby exerting a preventive or therapeutic effect on COVID-19 (106) , and also for NRICM101 (107) and MXSGD (74) . Network pharmacology has shown that the In the infected airway epithelium, SARS-CoV-2 can activate the mitogen-activated protein kinases (MAPK) pathway by binding to Toll-like receptors (TLRs), in particular the p38 MAPK pathway. This can cause the immune system to overreact and produce a variety of inflammatory mediators, called a "cytokine storm" (111) , characterized by the release of high levels of IL-6, IL-1β, and TNF-α (112, 113) . The presence of C-reactive protein, D-dimer, ferritin, and IL-6 is associated with an increase in major complications and mortality (114) . The autopsy of patients who died from COVID-19 showed that lymphocytic endotheliitis with apoptotic bodies and viral inclusion structures exists in multiple organs, including the lungs, heart, kidneys, and intestines (115, 116) . Obvious inflammation with endotheliitis can also lead to diffuse intravascular coagulation with thrombosis and infarction of the small or large vessels (117) . Overproduction of IL-6 may aggravate inflammation and tissue damage (118) . Increasing evidence indicates that an excessive inflammatory response to SARS-CoV-2 is an important factor in the severity of COVID-19-related disease and death (119, 120) . These data suggest that the cytokine storm is the basis of the immunopathology of severe COVID-19 (121) . Recently, it has been proposed that Liushen capsules are mainly composed of gamabufotalin, arenobufagin, telocinobufagin, desacetylcinobufotalin, bufotalin, and cinobufotalin. Cytopathic effect inhibition and plaque reduction assays reveal that it can reduce the expression J o u r n a l P r e -p r o o f of mRNA of TNF-α, IL-6, IL-1β, IL-8 (125) . The active ingredients and candidate targets of HSYF were obtained through database mining, and a "HSYF-herbal-components-targets-pathways-COVID-19" network was constructed.

In the central target analysis, the highest central target IL-6 and ACE2 were selected for molecular docking analysis, which revealed good binding activity (126).

Patients with COVID-19 often show specific immune function abnormalities, including activation of immune invisibility, paralysis, and memory. Compared to SARS-CoV, SARS-CoV-2 may cause a weak immune response or "immune stealth", which prolongs the patient's recovery process (22) . In the context of cytokine release syndrome, the production of the anti-inflammatory cytokine IL-10 is usually related to the downregulation of neutrophil and monocyte function, which is termed immune paralysis (127) and is crucial for survival (128) . While IL-1β drives macrophage activation syndrome, IL-6 drives immune disorders (129) . SARS-CoV-2 and the destruction of lung cells trigger a local immune response, recruiting macrophages and J o u r n a l P r e -p r o o f monocytes that respond to the infection, releasing cytokines and triggering adaptive T and B cell immune responses. In most cases, this process will resolve the infection.

However, in some cases, a dysfunctional immune response can occur, which can lead to severe lung disease and even systemic pathology (104) . If the patient is infected with SARS-CoV-2, the immune memory due to the previous infection with the low pathogenic coronavirus will be activated. Memory B cells rapidly produce cross-reactive antibodies. Fc receptors mediate viral antibody complexes into monocytes/macrophages, resulting in antibody-dependent enhancement. The virus replicates after immune escape, resulting in a rapid increase of its offspring, the release of a variety of pro-inflammatory cytokines, a reduction in lymphocytes, immune disorders, and resultant severe and critical illness in patients with COVID-19 (130) . Metabolic-related diseases such as hypertension, coronary heart disease, type 2 diabetes, metabolic syndrome, and obesity can downregulate key mediators of the host's innate immune response to pathogenesis, thereby affecting the function of the innate and humoral immune system (131, 132) . 

Chinese cardiologists reported that patients who died of COVID-19 presented with diffuse microvascular thrombosis in various organs, especially in the lungs. In severe COVID-19, severe coagulation activation and consumption of coagulation factors occur (134, 135) , often resulting in thrombotic complications (136) . Considering this diffuse thrombosis, Chinese physicians recommend that patients are treated with anticoagulant therapy (137) . First, the body's anti-disease process, including neutrophil extracellular traps (NETs) and increased D-dimer levels, leads to abnormal blood coagulation. As part of the immune response, white blood cells release NETs to capture and kill pathogens and help fight COVID-19 (138) . In severe infections, NETs can block blood vessels and cause inflammatory tissue damage (139, 140) . In addition to pulmonary embolism, COVID-19 can also cause sepsis-related disseminated intravascular coagulation, defined as "septicemia-induced coagulopathy" (141) . The blood of patients with underlying diseases tends to coagulate. Diabetes is associated with elevated plasminogen levels, which is thought to increase the virulence of SARS CoV-2 (142) . The presence of these inflammatory and thrombotic factors has been confirmed in 174 hospitalized patients with COVID-19 in Wuhan, China; the serum D-dimer level in patients with diabetes was significantly higher than in patients without diabetes (143) . The cytokine storm and hypoxia can also aggravate the outcome of blood coagulation. For example, hypercoagulability caused by inflammation may lead to plaque rupture, which can lead to thrombosis and myocardial damage (144) . As mentioned earlier, COVID-19 infection may cause endothelial dysfunction and a hypercoagulable state. Hypoxia can exacerbate this condition as well as increase thrombosis by increasing the blood viscosity and hypoxia-induced transcription factor-dependent signaling pathways (145) . Therefore, the prior introduction can reduce the harm caused by the cytokine storm and indirectly attenuate coagulation abnormalities. 

Severe pneumonia can cause severe gas exchange disorders and lead to hypoxemia.

Acidosis and the oxygen free radicals that accumulate in cells destroy the phospholipid layer of the cell membrane. As hypoxia continues, the intracellular calcium ion concentration increases significantly, leading to a series of cell damage processes, including cell apoptosis (147) . At the same time, hypoxia can also induce inflammatory responses, such as the infiltration of inflammatory cells and the release of cytokines, leading to further tissue ischemia and possibly even myocardial infarction (148) . It can be speculated that these genes play a key role in the mechanism of Da Yuan Yin treatment of COVID-19. IL-Iβ represents a wide range of inflammatory mediators and pathways. During the treatment of COVID-19, Da Yuan Yin can regulate IL-Iβ to exert its anti-hypoxia function (133).

As of mid-September 2020, more than 200 countries and territories around the world 

At present, the COVID-19 epidemic has lasted for nearly 12 months and the number of globally confirmed cases and deaths continue to rise. Current literature shows that four candidate drugs, including remdesivir, are ineffective or have little effect on COVID-19. Supportive treatments, such as oxygen inhalation, antibiotics, and antiviral drugs, remain the mainstay. Presently, there is good evidence that TCM can effectively alleviate the symptoms of patients with suspected and confirmed COVID-19, delay the progression from mild and moderate to severe and critical disease, and reduce severe and critical all-cause mortality. The role of TCM is related to affecting the transcription, replication, and binding of SARS-CoV-2 to the host and attenuating the cytokine storm and weak immunity in patients with COVID-19.

However, considering the deteriorating global epidemic situation, we must also consider formulating international guidelines for patients with COVID-19 from other countries, territories, and ethnicities, in order for TCM to serve patients around the world. At the same time, we must pay attention to PCSS and provide a complete chain of evidence for the prevention, treatment, and recovery using TCM. 

Emergence of genomic diversity and recurrent mutations in SARS-CoV-2

A Novel Coronavirus from Patients with Pneumonia in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Ultrastructural characterization of SARS coronavirus

On the origin and continuing evolution of SARS-CoV-2. National Science Review

The implications of silent transmission for the control of COVID-19 outbreaks

RNA Virus Fidelity Mutants: A Useful Tool for Evolutionary Biology or a Complex Challenge? Viruses

The not-so-infinite malleability of RNA viruses: Viral and cellular determinants of RNA virus mutation rates

Profile of a killer: the complex biology powering the coronavirus pandemic

Association of Cardiovascular Disease With Coronavirus Disease

COVID-19) Severity: A Meta-Analysis

Tobacco Smoking Increases the Lung Gene Expression of ACE2, the Receptor of SARS-CoV-2

Activation of the GLP-1 Receptor by

Liraglutide Increases ACE2 Expression, Reversing Right Ventricle Hypertrophy, and Improving the Production of SP-A and SP-B in the Lungs of Type 1 Diabetes Rats

Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2

atorvastatin: role of epigenetic histone modifications

Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist

Pioglitazone upregulates angiotensin converting enzyme 2 expression in insulin-sensitive tissues in rats with high-fat diet-induced nonalcoholic steatohepatitis

Long-term infection of SARS-CoV-2 changed the body's immune status

Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Cell entry mechanisms of SARS-CoV-2

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Coronavirus endoribonuclease targets viral polyuridine sequences to evade activating host sensors

Innate immunity during SARS-CoV-2: evasion strategies and activation trigger hypoxia and vascular damage

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study

COVID-19: consider cytokine storm syndromes and immunosuppression

COVID-19: the case for health-care worker screening to prevent hospital transmission

Cardiovascular Complications and Short-term Mortality Risk in Community-Acquired Pneumonia

Compassionate Use of Remdesivir for Patients with Severe Covid-19

Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

COVID-19 Vaccine Frontrunners and Their Nanotechnology Design

Covid-19: UK approves Oxford vaccine as cases of new variant surge

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine -United States

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

Traditional Chinese medication for cardiovascular disease

Traditional Chinese Medicine for Cardiovascular Disease: Evidence and Potential Mechanisms

Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula

Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial

Clinical Characteristics of Coronavirus Disease 2019 in China

Manifestations and prognosis of gastrointestinal and liver

Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment

Yidu-toxicity blocking lung decoction ameliorates inflammation in severe pneumonia of SARS-COV-2 patients with Yidu-toxicity blocking lung syndrome by eliminating IL-6 and TNF-a

Contribution of traditional Chinese medicine to the treatment of COVID-19

Hanshiyi Formula, a medicine for Sars-CoV2 infection in China, reduced the proportion of mild and moderate COVID-19 patients turning to severe status: A cohort study

Analysis of influencing factors of death in patients with COVID-19

Chinese herbal medicine reduces mortality in patients with severe and critical Coronavirus disease 2019: a retrospective cohort study

Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction

Study on the overall regulation of Xuebijing injection in treating COVID-19

Traditional Chinese medicine network pharmacology study on exploring the mechanism of Xuebijing Injection in the treatment of coronavirus disease 2019

Transcriptional suppression of androgen receptor by 18beta-glycyrrhetinic acid in LNCaP human prostate cancer cells

Effective inhibition of MERS-CoV infection by resveratrol

Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-kappaB signaling pathway

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)

Immunotherapeutic implications of IL-6 blockade for cytokine storm

Kaempferol regulates MAPKs and NF-κB signaling pathways to attenuate LPS-induced acute lung injury in mice

The Immunomodulatory and Anti-Inflammatory Role of Polyphenols

Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach

Deciphering the Pharmacological Mechanisms of Ma Xing Shi Gan Decoction against COVID-19 through Integrating Network Pharmacology and Experimental Exploration

Utilizing integrating network pharmacological approaches to investigate the potential mechanism of Ma Xing Shi Gan Decoction in treating COVID-19

Quercetin supports cell viability and inhibits apoptosis in cardiocytes by down-regulating miR-199a

ORF1b-encoded nonstructural proteins 12-16: replicative enzymes as antiviral targets

Understanding helicases as a means of virus control

Design of wide-spectrum inhibitors targeting coronavirus main proteases

Glycyrrhizin inhibits highly pathogenic H5N1 influenza A virus-induced pro-inflammatory cytokine and chemokine expression in human macrophages

Antiviral activity of glycyrrhizic acid derivatives against SARS-coronavirus

Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: a pharmacoinformatics study

Theoretical study of the anti-NCP molecular mechanism of traditional Chinese medicine Lianhua-Qingwen formula (LQF)

Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

Targeting membrane-bound viral RNA synthesis reveals potent inhibition of diverse coronaviruses including the middle East respiratory syndrome virus

Viral metagenomics, protein structure, and reverse genetics: Key strategies for investigating coronaviruses

The spike protein of SARS-CoV--a target for vaccine and therapeutic development

Structure of the 2019-nCoV Spike in the Prefusion Conformation

Exceptional flexibility in the sequence requirements for coronavirus small envelope protein function

Coronavirus envelope (E) protein remains at the site of assembly

Coronavirus envelope protein: current knowledge

SARS coronavirus papain-like protease inhibits the type I interferon signaling pathway through interaction with the STING-TRAF3-TBK1 complex

The papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiquitinating enzyme

Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases

Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus

Towards treatment planning of COVID-19: Rationale and hypothesis for the use of multiple immunosuppressive agents: Anti-antibodies, immunoglobulins, and corticosteroids

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

COVID-19 and the cardiovascular system

Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2

The trinity of COVID-19: immunity, inflammation and intervention

Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus

Research on active herbal medicine

A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study

Single-cell RNA-seq data

The Nrf2 Activator (DMF) and Covid-19: Is there a Possible Role? Med Arch

Clinical and immunological features of severe and moderate coronavirus disease 2019

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Endothelial cell infection and endotheliitis in COVID-19

Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome

IL-6 as a keystone cytokine in health and disease

Roles of inflammation, oxidative stress, and vascular dysfunction in hypertension

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Immunopathology of Hyperinflammation in COVID-19

Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy

Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and

Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study

Active constituents and mechanisms of Respiratory Detox Shot, a traditional Chinese medicine prescription, for COVID-19 control and prevention: Network-molecular docking-LC-MS(E) analysis

Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway

Immunoparalysis and adverse outcomes from critical illness

Complex Immune Dysregulation in

Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines

Obesity and the risk and outcome of infection

Connecting type 1 and type 2 diabetes through innate immunity. Cold Spring Harb Perspect Med

Mechanism of molecular docking

Abnormal coagulation parameters are

COVID-19 Presented With Deep Vein Thrombosis: An Unusual Presenting

Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis?

Beneficial suicide: why neutrophils die to make NETs

Neutrophil Extracellular Traps in Atherosclerosis and Atherothrombosis

Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation

Elevated Plasmin(ogen) as a

Common Risk Factor for COVID-19 Susceptibility

Altered preoperative coagulation and fibrinolysis are associated with myocardial injury after non-cardiac surgery

The stimulation of thrombosis by hypoxia

Hemostatic effects of ephedrine

Effect of oxygen deprivation on the metabolism of fetal and adult tissues

Contemporary Diagnosis and Management of Patients With Myocardial Infarction in the Absence of Obstructive Coronary Artery Disease: A Scientific Statement From the

International traditional Chinese medicine guideline for diagnostic and treatment principles of diabetes

Altered Lipid

Zhejiang Da Xue Xue Bao Yi Xue Ban

Retrospective study

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)

Network pharmacology-based analysis of the role of traditional Chinese herbal medicines in the treatment of COVID-19

Biomed Pharmacother. with oxygen, antivirals (such as interferon or ribavirin), antibiotics (such as moxifloxacin, cefoperazone sodium, and sulbactam sodium), and Chinese medicine based on the Diagnosis and Treatment Guideline for COVID-19

Kuxingren (Prunus armeniaca L. var. ansu Maxim.), Baizhu (Atractylodes macrocephala Koidz

Abbreviation: TCM: traditional Chinese medicine; WM: Western medicine; COVID-19: Corona Virus Disease 2019; IL-6: Interleukin 6; IL-8: Interleukin 8;, IL-2R: Interleukin 2R;, TNF-α: Tumor necrosis factor α; HSYF: HanShiYi formula; LHQWC: Lianhua Qingwen Capsules; HXZQG: Huoxiang Zhengqi Granules

Not Applicable